0001079973-18-000404.txt : 20180627 0001079973-18-000404.hdr.sgml : 20180627 20180627160732 ACCESSION NUMBER: 0001079973-18-000404 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180627 ITEM INFORMATION: Other Events FILED AS OF DATE: 20180627 DATE AS OF CHANGE: 20180627 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nemaura Medical Inc. CENTRAL INDEX KEY: 0001602078 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38355 FILM NUMBER: 18921880 BUSINESS ADDRESS: STREET 1: ADVANCED TECHNOLOGY INNOVATION CENTRE STREET 2: LOUGHBOROUGH UNIV SCIENCE & ENTERPRISE CITY: 5 OAKWOOD DRIVE, LOUGHBOROUGH STATE: X0 ZIP: LE11 3QF BUSINESS PHONE: 44-1509-222-912 MAIL ADDRESS: STREET 1: ADVANCED TECHNOLOGY INNOVATION CENTRE STREET 2: LOUGHBOROUGH UNIV SCIENCE & ENTERPRISE CITY: 5 OAKWOOD DRIVE, LOUGHBOROUGH STATE: X0 ZIP: LE11 3QF 8-K 1 nemaura_8k.htm FORM 8-K


SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
 the Securities Exchange Act 1934
Date of Report (Date of earliest event reported): June 27, 2018
 
 
NEMAURA MEDICAL, INC.
 
 
(Exact name of registrant as specified in charter)
 
 
 
 
 
Nevada
 
 
(State or other jurisdiction of incorporation)
  
 
 
001-38355
 
  
 
46-5027260
 
(Commission File Number)
  
(IRS Employer Identification No.)
     
Advanced Technology Innovation Centre,
Loughborough University Science and Enterprise Parks,
5 Oakwood Drive,
Loughborough, Leicestershire LE11 3QF
United Kingdom
 
N/A
(Address of principal executive offices)
(Zip Code)
     
Registrant’s telephone number, including area code:
00 44 1509 222912
 
________________________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
 
Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.  Other Events
 
Nemaura Medical, Inc. (the “Registrant”), has terminated the public offering of shares of its common stock which was being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission on March 31, 2016.  The termination results from an assessment by the Company's management that a public offering on the terms provided would not be in the best interests of the Company's shareholders. As a result of such termination, no shares will be sold pursuant to the offering.

 


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Nemaura Medical, Inc.
 
By: /s/ Dewan F. H. Chowdhury       
Name: Dewan F. H. Chowdhury
 Title:   Chief Executive Officer
 
Dated: June 27, 2018